Sacubitril/缬沙坦与缬沙坦患者naïve对肾素-血管紧张素系统抑制剂的起始：来自PARAGLIDE-HF的见解

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2025-01-10 DOI:10.1002/ejhf.3579

Nina Nouhravesh, Alexander H. Gunn, Derek Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, Samiha Sarwat, Kavita Sharma, Kristin M. Williamson, Randall C. Starling, Serge Lepage, Shelley Zieroth, Scott D. Solomon, Robert J. Mentz

{"title":"Sacubitril/缬沙坦与缬沙坦患者naïve对肾素-血管紧张素系统抑制剂的起始：来自PARAGLIDE-HF的见解","authors":"Nina Nouhravesh, Alexander H. Gunn, Derek Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, Samiha Sarwat, Kavita Sharma, Kristin M. Williamson, Randall C. Starling, Serge Lepage, Shelley Zieroth, Scott D. Solomon, Robert J. Mentz","doi":"10.1002/ejhf.3579","DOIUrl":null,"url":null,"abstract":"Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"22 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE-HF\",\"authors\":\"Nina Nouhravesh, Alexander H. Gunn, Derek Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, Samiha Sarwat, Kavita Sharma, Kristin M. Williamson, Randall C. Starling, Serge Lepage, Shelley Zieroth, Scott D. Solomon, Robert J. Mentz\",\"doi\":\"10.1002/ejhf.3579\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2025-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3579\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3579","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

目前尚不清楚先前接受血管紧张素转换酶抑制剂（ACEi）或血管紧张素受体阻滞剂（ARBs）治疗是否会改变舒比利/缬沙坦（Sac/Val）在心力衰竭（HF）和射血分数（EF） 40%患者中的疗效和安全性，因此根据ACEi/ARB基线状态评估Sac/Val。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE-HF

查看原文本刊更多论文

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE-HF

Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.